Table 1.
Main features of the included studies in the current meta-analysis.
| Author | Year | Country | Number of Patients | Cut-Off for PD-L1 (Positive/High Expression) |
Cut-Off for TIL (Positive/High Expression) |
PD-L1 Evaluation Method | TILs Evaluation Method | Follow-Up Time |
Endpoint | Number of Patients with Experience of ICIs | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M. Okabe [18] | 2017 | Japan | 21 | H-score > 3 | ≥50% | IHC | IHC | 127.3 | OS/DFS | 0 |
| 2 | N. AiErken [17] | 2017 | China | 215 | positive (>1) | (41% to 100%) | IHC | IHC | 67.7 (7–159) | OS/DFS | N/a |
| 3 | R. K. Beckers [16] | 2015 | Australia | 161 | H-score >100 | (score 3) > 60% | IHC | H&E | 55 (0–213) | OS/DFS | N/a |
| 4 | H. Mori [15] | 2017 | Japan | 248 | ≥50% | ≥50% | IHC | H&E | 68 (2–150) | OS/DFS | N/a |
| 5 | M. V. Dieci [13] | 2018 | Italy | 43 | ≥5% | ≥10% | IHC | H&E | unclear | OS | N/a |
| 6 | J. Yeong [14] | 2019 | Singapore | 269 | unclear | unclear | IHC | IHC | 97 (1–213) | OS/DFS | N/a |
| 7 | X. Ren [27] | 2018 | China | 195 | >25% | (score 3) > 60% | IHC | H&E | unclear | OS/DFS | N/a |
Abbreviations: PD-L1: programmed death-ligand 1, TIL: tumor-infiltrating lymphocytes, ICIs: immune checkpoint inhibitors, N/a: not available, IHC: immunohistochemistry, H&E: hematoxylin and eosin.